<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02891590</url>
  </required_header>
  <id_info>
    <org_study_id>DTRM_DTRMWXHS-12_001</org_study_id>
    <nct_id>NCT02891590</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas</brief_title>
  <official_title>Phase Ia Study of the Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang DTRM Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang DTRM Biopharma</source>
  <brief_summary>
    <textblock>
      The Primary Objective is to evaluate the safety and tolerability of multiple dose oral
      administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma.

      The Secondary Objective is to evaluate the pharmacokinetics of multiple dose oral
      administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Starting from date of first dose up to 30 days after last dose</time_frame>
    <description>Confirm the safety and tolerability of multiple dose oral administration of DTRMWXHS-12 capsule</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of DTRMWXHS-12</measure>
    <time_frame>Days 1-28 (first treatment cycle)</time_frame>
    <description>DTRMWXHS-12 Pharmacokinetics</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>B-cell Lymphomas</condition>
  <arm_group>
    <arm_group_label>DTRMWXHS-12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTRMWXHS-12 only: oral capsules (50 mg and 150 mg strengths), successive administration, dose escalation from 50mg to 100, 200, 400, 600, 800mg daily until MTD. During successive administration, orally once a day, 28 days as a cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTRMWXHS-12</intervention_name>
    <arm_group_label>DTRMWXHS-12</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age≥18 years, gender is not limited. Patients are voluntary to sign the informed
             consent form.

          -  B-Cell Lymphoma based on WHO classified definition: including chronic lymphocytic
             leukemia (CLL)/ small lymphocytic lymphoma (SLL); chronic lymphocytic leukemia with
             17p-; mantle cell lymphoma (MCL); Waldenstrom's macroglobulinemia(WM); Diffuse large
             B-cell lymphoma (DLBL or DLBCL) etc.

          -  Measurable lesion: non-Hodgkin 's lymphoma requires at least a two-dimensional lesion
             diameter ≥ 2 cm, chronic lymphocytic leukemia ≥ 5000 leukemia cells / mm3,
             Waldenstrom's macroglobulinemia IgM ≥ 1000 mg / dL, bone marrow lymph plasma -like
             cells infiltration, Histopathologically diagnosed as Diffuse Large B- Cell Lymphoma.

          -  Investigator judges that the treatment is needed.

          -  Patients, who at least failed in lymphoma treatment once and without standard
             therapeutic options, can't satisfy the requirement or decline treatment or failed in
             autologous stem cell transplantation for Diffuse Large B- Cell Lymphoma.

          -  ECOG (Eastern Cooperative Oncology Group) performance status 0 ~1

          -  Life expectancy greater than 4 months

          -  Ability to swallow capsules

          -  Hematologic functions satisfy: Neutrophils ≥1.5×109 / L ( according to the
             investigators' opinion , if they judge that the patients' neutrophil count lower than
             this threshold, which caused by chronic lymphocytic leukemia and bone marrow
             infiltration, those patients are eligible to be included. ), platelet(PLT) ≥75×109/L,
             HB≥80g/L

          -  Renal functions satisfy: Creatinine (Cr) ≤ 1.5 times of upper limit of normal persons;
             creatinine clearance rate≥50ml/min (estimated by Cockcroft-Gault formula or detected
             by nuclear medicine scan or 24 hours urine method)

          -  Liver functions satisfy: AST and ALT≤2.5 times of normal value, bilirubin ≤1.5 times
             of normal value

          -  Coagulation function: international normalized ratio (INR) and APTT ≤ 1.5 times of
             normal value;

          -  Throughout the course of the study and 90 days of treatment interruption, female of
             childbearing age and fertile males who must take one of the following effective
             contraception measures: abstinence, barrier-type dual contraceptive methods, IUDs,
             administration of hormonal contraception drug.

          -  Male subjects are prohibited sperm donation from the start to the end of treatment
             within 90 days.

        Exclusion Criteria:

          -  Patients with brain metastasis

          -  Disease with changes of pathological tissue types (including large cell
             transformation)

          -  Patients who received allogeneic stem cell transplantation within 6 months, or with
             organized incompatibility reaction (GVHD), requires immunosuppressive therapy

          -  Patients who received steroid anti-tumor therapy within 7 days, or receive
             chemotherapy within 2 weeks, or receive monoclonal antibody therapy within 4 weeks,
             prior to first administration of DTRMWXHS-12 capsule.

          -  Patients received other BTK inhibitor therapy

          -  Patients had early received chemotherapy but their toxicity has not been cleared
             (according to NCI-CTCAE 4.03, unrecovered toxicity grade ≤1)

          -  Patients who received Chinese herbal anti-tumor therapy within 1 week before the start
             of study

          -  Patient with a history of other malignant within 2 years before enrollment, except (1)
             adequately treated in situ cervical cancer;(2) Local basal cell carcinoma or squamous
             cell carcinoma (3) Local malignant tumor which has been completely treated (by surgery
             or other means)

          -  Patients with uncontrolled systemic infection requiring intravenous anti-infection
             treatment

          -  Patients received major surgery in the past 4 weeks

          -  Patients with HIV infection, HBs-Ag positive

          -  According to New York Heart Association (NYHA) classification, patients with
             cardiovascular disease of grade ≥3

          -  Patients with history of Myocardial infarction, acute coronary syndrome (unstable
             angina), receiving coronary angioplasty and stent implantation within 6 months of
             study entry

          -  Patients applied something which may cause QT prolongation or accompany by torsades
             healer within 7 days prior to enrollment.

          -  Prolonged QTc interval (defined as a QTc&gt; 450 ms) or other significant ECG
             abnormalities, including second degree atrioventricular block type Ⅱ, third degree
             atrioventricular block, or bradycardia (heart rate less than 50 beats / min),ECG QTc&gt;
             450 milliseconds, the ECG may be submitted to expert for centralized evaluation

          -  Subjects, the investigators think whose existing renal disease, neurological /
             psychiatric disorders, liver or endocrine disorders could affect their participating
             in the experiment

          -  Subjects with poor compliance

          -  Subjects are using CYP3A inhibitors (or inducer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei He, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Zhejiang DTRM Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phone Number</last_name>
      <phone>86-1088121122</phone>
    </contact>
    <investigator>
      <last_name>Jun Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

